Mechanism of action of Montelukast is:
Wait, there are different types of leukotriene receptors. CysLT1 and CysLT2. Montelukast is a selective CysLT1 receptor antagonist, right? So it blocks the action of leukotrienes at the CysLT1 receptor. That would prevent the bronchoconstriction, increased vascular permeability, and other inflammatory effects associated with leukotrienes.
Now, looking at the options. The question doesn't have specific options listed, but the correct answer is likely to be that Montelukast inhibits CysLT1 receptors. The other options could be things like H1 antagonists, beta-2 agonists, or maybe 5-lipoxygenase inhibitors. Let me think: Zileuton is a 5-lipoxygenase inhibitor, which prevents leukotriene synthesis. Montelukast is a receptor antagonist, not an enzyme inhibitor. So if an option says it's a 5-lipoxygenase inhibitor, that's incorrect.
Another possible wrong option could be a mast cell stabilizer, like cromolyn. Or maybe a PDE-4 inhibitor, such as roflumilast. Also, maybe an option about blocking IgE receptors, like omalizumab. Each of these has different mechanisms. So I need to explain why each of these is wrong in the explanation.
The core concept here is the role of leukotrienes in inflammation and how Montelukast works. The clinical pearl would be that Montelukast is a leukotriene receptor antagonist, specifically CysLT1, used for asthma and allergies. Students might confuse it with other anti-inflammatory agents, so it's important to distinguish between receptor antagonists and enzyme inhibitors.
I need to structure the explanation with the required sections: Core Concept, Why Correct Answer is Right, Why Each Wrong Option is Incorrect, Clinical Pearl, and Correct Answer. Let me check the character count to stay within limits. Also, use bold for key terms and avoid markdown beyond that. Make sure the explanation is concise but thorough.
**Core Concept**
Montelukast is a leukotriene receptor antagonist that selectively inhibits the cysteinyl leukotriene (CysLT) type 1 receptor. Leukotrienes (LTs), particularly LTC4, LTD4, and LTE4, mediate bronchoconstriction, vascular permeability, and inflammation via this receptor, contributing to asthma and allergic rhinitis pathogenesis.
**Why the Correct Answer is Right**
Montelukast blocks CysLT1 receptors, preventing leukotriene-induced bronchoconstriction, mucus secretion, and eosinophil recruitment. By inhibiting these inflammatory pathways, it reduces airway hyperresponsiveness and improves asthma control. Unlike LTRA alternatives (e.g., zafirlukast), it has better CNS penetration but is not used for CNS indications.
**Why Each Wrong Option is Incorrect**
**Option A:** *5-L